Siphene 100 mg (Clomiphene)

Product Overview

Siphene 100 mg is a prescription medication containing clomiphene citrate, a selective estrogen receptor modulator used to treat female infertility caused by ovulatory problems. Produced by Serum Institute India, it is supplied in strips of five film‑coated tablets, each delivering exactly 100 mg of the active ingredient. Pack sizes of 30, 60, or 90 tablets are available, allowing clinicians to tailor treatment length. The tablets are taken orally and should be stored at room temperature away from moisture. Typical delivery time ranges from six to fifteen days, depending on the shipping destination. According to the NIH, clomiphene citrate has a well‑documented mechanism of action in fertility treatment.

What is Siphene 100 mg

Siphene belongs to the class of non‑steroidal fertility agents known as clomiphene citrate. It works by binding to estrogen receptors in the hypothalamus, which reduces negative feedback and stimulates the release of gonadotropin‑releasing hormone. This prompts the pituitary gland to increase secretion of follicle‑stimulating hormone and luteinizing hormone, encouraging the development of multiple ovarian follicles. The resulting rise in estrogen levels can trigger ovulation in women who have difficulty conceiving naturally. Siphene is prescribed when ovulatory dysfunction is identified as the primary barrier to pregnancy.

Uses and Benefits

The main indication for Siphene 100 mg is the induction of ovulation in women with polycystic ovary syndrome, hypothalamic amenorrhea, or other forms of anovulation. By stimulating the growth of one or more ovarian follicles, the drug increases the probability of successful fertilization when intercourse or intrauterine insemination is timed appropriately. Compared with more invasive assisted‑reproductive techniques, Siphene offers a cost‑effective first‑line option and is often incorporated into treatment protocols that include ultrasound monitoring. Clinical studies report pregnancy rates of roughly 10 % to 15 % per cycle when the medication is used according to established guidelines.

How It Works

Clomiphene citrate acts as a selective estrogen receptor modulator that antagonizes estrogen receptors in the hypothalamus, leading to an increase in gonadotropin‑releasing hormone pulsatility. The resulting rise in follicle‑stimulating hormone and luteinizing hormone levels promotes the development of multiple ovarian follicles. Unlike full estrogen agonists, clomiphene exhibits partial agonist activity in peripheral tissues while maintaining antagonistic effects in the brain, which helps avoid estrogenic stimulation of breast or uterine tissue. This selective profile enables the drug to induce ovulation without exerting strong estrogenic effects elsewhere, contributing to its favorable safety profile at recommended doses.

Dosage Guidelines

Standard dosing of Siphene involves taking one 100 mg tablet daily for five consecutive days, usually commencing on the fifth day of a regular menstrual cycle. After the course, clinicians monitor follicular growth via ultrasound or hormone assays to determine whether ovulation has occurred. If adequate follicular development is observed, timed intercourse or intrauterine insemination can be scheduled. When ovulation does not happen, a second five‑day course may be considered after a brief wash‑out period, but treatment should generally not exceed six cycles without a clear therapeutic benefit. Dose adjustments are not required for mild hepatic impairment, though caution is advised in patients with significant renal disease or known hypersensitivity to clomiphene. For detailed prescribing information, refer to the FDA.

Side Effects

Adverse reactions to Siphene are generally mild and self‑limiting. The most common side effects include hot flashes, abdominal discomfort, and breast tenderness. Some users experience visual disturbances such as blurred vision or floaters, which typically resolve after discontinuation. Less frequent but clinically important events include ovarian hyperstimulation syndrome, characterized by abdominal distension, pelvic pain, and rapid weight gain, as well as mood changes like irritability or depression. Rarely, thromboembolic events have been reported, especially in women with underlying risk factors. Patients should report persistent or severe symptoms to their physician promptly.

Warnings and Precautions

Siphene is contraindicated in pregnant women and should not be used if a pelvic mass of unknown etiology is present. Prior to initiation, a full medical history must be reviewed to identify conditions such as liver disease, ovarian cysts, or abnormal vaginal bleeding that require further investigation. Women with a history of thromboembolic disorders or those taking anticoagulant medications should be evaluated carefully, as the drug may increase clotting risk. Therapy is usually limited to a maximum of six treatment cycles unless a clear benefit is documented, thereby reducing the potential for long‑term hormonal disruption. Concomitant use of hormonal contraceptives is generally discouraged during clomiphene treatment because it may blunt the expected ovulatory response. Patients should adhere strictly to prescribed dosing and attend all scheduled monitoring appointments. Additional safety details can be found at MedlinePlus.

Frequently Asked Questions

1. Question 1: How should Siphene be stored?
   Answer: Siphene tablets should be kept at room temperature, away from moisture and direct sunlight. Keep the strip sealed until ready to use, and store it out of reach of children.
2. Question 2: Can Siphene be used together with other fertility treatments?
   Answer: Yes, Siphene can be combined with timed intercourse or intrauterine insemination. It is sometimes used before in‑vitro fertilization, but clinicians typically avoid using it alongside aggressive gonadotropin stimulation to reduce the risk of ovarian hyperstimulation.
3. Question 3: How long does it take to see results after starting Siphene?
   Answer: Follicular development is usually detectable within seven to ten days after the five‑day course, and ovulation may occur 24 to 36 hours after the luteinizing hormone surge. Pregnancy, if it occurs, is typically confirmed within two weeks of the expected ovulation window.
4. Question 4: Are there any dietary restrictions while taking Siphene?
   Answer: No specific foods must be avoided, but a balanced diet low in excess caffeine and alcohol is recommended. Maintaining a healthy body weight and staying hydrated can support optimal ovulatory response.
5. Question 5: What should I do if I miss a dose of Siphene?
   Answer: If a dose is missed, simply skip it and continue with the regular schedule the next day. Do not double up on tablets. If multiple doses are missed within the same cycle, contact your healthcare provider for further guidance.

Related Products

• CB-Lin (Cabergoline)
• Meprate 10 mg (Medroxyprogesterone)
• Sicriptin 2.5 mg Tablets (Bromocriptine)
• Sicriptin 1.25 mg Tablets (Bromocriptine)
• Sicriptin (Bromocriptine)
• Bromocriptine 1.25 mg (Generic)
• Bromocriptine 2.5 mg (Generic)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 50 mg (Generic)